BNTX
MSD
PFE
Pfizer goes shopping in oncology
Pfizer didn’t exactly send a polite LinkedIn message here — it dropped a $6 billion licensing deal on China’s 3SBio for SSGJ-707, a PD-1/VEGF bispecific that’s already in clinical testing for a handful of cancers.
The upfront check alone is chunky: $1.2 billion in cash, plus a $100 million equity investment in 3SBio. That’s the kind of money that says, “We want in now, and we’re not waiting for a bake sale.”
Why investors should care
This is Pfizer trying to muscle into one of oncology’s hottest lanes. PD-1/VEGF drugs are being pitched as the next big swing in cancer therapy — the sort of thing that could eventually nibble at Merck’s Keytruda dominance if the data cooperate.
The timing matters too. 3SBio said a phase 3 program is due to start later this year, so this isn’t some distant science-fair project. It’s a real pipeline bet with near-term development milestones, which means the story could keep moving from deal headlines to actual clinical data pretty quickly.
The bigger picture
Pfizer’s been working hard to reload its growth engine, and oncology remains one of the company’s best shots at finding the next blockbuster. Deals like this are expensive, sure, but in pharma land, expensive can still be cheaper than missing the next wave.
Big picture: Pfizer just paid a premium to get a seat at a very crowded, very lucrative table. If SSGJ-707 works, the upside is huge. If not, well, biotech continues to be the world’s priciest game of maybe.